4-Hydroxyphenylisocyanat | 23159-72-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-Hydroxyphenylisocyanat
• 英文别名: p-hydroxyphenyl isocyanate；4-isocyanato-phenol；4-hydroxyphenyl isocyanate；4-Isocyanatophenol
• CAS: 23159-72-0
• 化学式: C₇H₅NO₂
• 分子量: 135.122
• InChiKey: DYKCDKICHOCWGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Hydroxyphenylisocyanat 在 水 、 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.05h， 以99%的产率得到1,3-双(4-羟基苯基)脲
  参考文献：
  名称：

  对称 1,3-二取代脲和硫脲的快速合成方法

  摘要：

  摘要 在室温下，在叔胺的存在下，通过一种通用、简单、快速的新方法，由相应的异氰酸酯、二异氰酸酯和异硫氰酸酯合成了对称的 1,3-二取代脲和对称硫脲。所讨论的方法与现有技术相比具有几个优点，因为它易于实施，不需要复杂的设备，后处理简单，并且不使用昂贵的化学品。此外，产量几乎是定量的。这种方法在商业应用中具有潜力。

  DOI：

  10.1081/scc-200061656
• 作为产物：
  描述：

  三光气 、 对氨基苯酚 在 三乙胺 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 8.5h， 生成 4-Hydroxyphenylisocyanat
  参考文献：
  名称：

  Synthesis and structure-activity relationship study of pyrrolidine-oxadiazoles as anthelmintics against Haemonchus contortus

  摘要：

  Parasitic roundworms (nematodes) are significant pathogens of humans and animals and cause substantive socioeconomic losses due to the diseases that they cause. The control of nematodes in livestock animals relies heavily on the use of anthelmintic drugs. However, their extensive use has led to a widespread problem of drug resistance in these worms. Thus, the discovery and development of novel chemical entities for the treatment of parasitic worms of humans and animals is needed. Herein, we describe our medicinal chemistry optimization efforts of a phenotypic hit against Haemonchus contortus based on a pyrrolidine-oxadiazole scaffold. This led to the identification of compounds with potent inhibitory activities (IC50 = 0.78-22.4 mu M) on the motility and development of parasitic stages of H. contortus, and which were found to be highly selective in a mammalian cell counter-screen. These compounds could be used as suitable chemical tools for drug target identification or as lead compounds for further optimization. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112100

文献信息

• Synthesis and SAR of New 5-Phenyl-3-ureido-1,5-benzodiazepines as Cholecystokinin-B Receptor Antagonists
  作者：Antonella Ursini、Anna M. Capelli、Robin A. E. Carr、Paolo Cassarà、Mauro Corsi、Ornella Curcuruto、Giovanni Curotto、Michele Dal Cin、Silvia Davalli、Daniele Donati、Aldo Feriani、Harry Finch、Gabriella Finizia、Giovanni Gaviraghi、Marc Marien、Giorgio Pentassuglia、Stefano Polinelli、Emiliangelo Ratti、Aldo Reggiani、Giorgio Tarzia、Giovanna Tedesco、Maria E. Tranquillini、David G. Trist、Frank T. M. Van Amsterdam

  DOI：10.1021/jm990967h

  日期：2000.10.1

  A series of 5-phenyl-3-ureidobenzodiazepine-2,4-diones was synthesized and evaluated as cholecystokinin-B (CCK-B) receptor antagonists. Structure-activity relationship (SAR) studies revealed the importance of the N-1 substituent for potent and selective CCK-B affinity. Addition of substituents at the urea side chain provided in some cases more potent compounds. Moreover the introduction of bulky substituents

  合成了一系列5-苯基-3-脲基苯并二氮杂-2，4-二酮，并作为胆囊收缩素-B（CCK-B）受体拮抗剂进行了评估。结构活性关系（SAR）研究表明，N-1取代基对于有效和选择性CCK-B亲和力的重要性。在某些情况下，在脲侧链上添加取代基可提供更有效的化合物。此外，在N-1处引入笨重的取代基（如金刚烷基甲基）和拆分外消旋脲导致了我们的铅化合物GV150013。
• Oxindole derivatives
  申请人：Luk Kim-Chun

  公开号：US20060293319A1

  公开（公告）日：2006-12-28

  The invention describes compounds of the general formula I or the pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 and X are herein described, a process for their manufacture, medicaments containing them as well as the use of these compounds as pharmaceutically active agents. The compounds show activity as antiproliferative agents and may be especially useful for the treatment of cancer.

  这项发明描述了一般式I的化合物或其药用盐，其中R1、R2、R3和X在此处描述，以及它们的制备方法、含有它们的药物以及将这些化合物用作药用活性剂的用途。这些化合物显示出抗增殖剂的活性，可能特别适用于癌症的治疗。
• [EN] DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE DIAMINOCYCLOHEXANE ET LEURS UTILISATIONS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013012829A1

  公开（公告）日：2013-01-24

  The present invention provides compounds of Formula (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 receptor and may be used for the treatment and prophylaxis of various diseases and conditions.

  本发明提供了Formula (I)的化合物或其立体异构体，或其药学上可接受的盐，其中所有变量均如本文所定义。这些化合物是NPY Y4受体的激动剂、部分激动剂和调节剂，可用于治疗和预防各种疾病和症状。
• Identification of Inhibitors of the Leishmania cdc2-Related Protein Kinase CRK3
  作者：Laura A. T. Cleghorn、Andrew Woodland、Iain T. Collie、Leah S. Torrie、Neil Norcross、Torsten Luksch、Chido Mpamhanga、Roderick G. Walker、Jeremy C. Mottram、Ruth Brenk、Julie A. Frearson、Ian H. Gilbert、Paul G. Wyatt

  DOI：10.1002/cmdc.201100344

  日期：2011.12.9

  focussed kinase set of ∼3400 compounds to identify potent and parasite‐selective inhibitors of an enzymatic Leishmania CRK3–cyclin 6 complex. The aim of this study is to provide chemical validation that Leishmania CRK3–CYC6 is a drug target. Eight hit series were identified, of which four were followed up. The optimisation of these series using classical SAR studies afforded low‐nanomolar CRK3 inhibitors

  迫切需要新药来治疗热带寄生虫病，例如利什曼病和非洲人类锥虫病 (HAT)。这项工作涉及对约 3400 种化合物的聚焦激酶组进行高通量筛选，以鉴定酶促利什曼原虫CRK3-细胞周期蛋白 6 复合物的有效和寄生虫选择性抑制剂。本研究的目的是提供化学验证，证明利什曼原虫CRK3–CYC6 是药物靶点。确定了八个热门系列，其中四个得到了跟进。使用经典 SAR 研究对这些系列进行优化，提供了比密切相关的人类细胞周期蛋白依赖性激酶 CDK2 具有显着选择性的低纳摩尔 CRK3 抑制剂。
• Synthesis and investigation of effects of 2-[4-[[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships
  作者：Iraj Lalezari、Parviz Lalezari

  DOI：10.1021/jm00130a021

  日期：1989.10

  series of 2-[4-[[[(substituted-phenyl)amino]carbonyl]amino]phenoxy]-2- methylpropionic acids and other substituted phenoxyacetic acids were synthesized and tested for their ability to reduce the affinity of hemoglobin for oxygen. 2-[4-[[[(3,4,5-trichlorophenyl)amino]carbonyl]amino]phenoxy]-2- methylpropionic acid was found to be the most potent compound known. Structure-activity relationships of the compounds

  合成了一系列2- [4-[[[[（（取代-苯基）氨基]羰基]氨基]苯氧基] -2-甲基丙酸和其他取代的苯氧基乙酸，并测试了它们降低血红蛋白对氧的亲和力的能力。发现2- [4-[[[（（3,4,5-三氯苯基）氨基]羰基]氨基]苯氧基] -2-甲基丙酸是已知的最有效的化合物。讨论了合成化合物的构效关系。